Postmarketing Surveillance Study of Erlotinib in Japanese Patients with Non-Small-Cell Lung Cancer (NSCLC): An Interim Analysis of 3488 Patients (POLARSTAR)

Journal of Thoracic Oncology

Volumn 7, Issue 8, 2012, Pages 1296-1303

  Nakagawa, Kazuhiko ^a,b   Kudoh, Shoji ^b,c   Ohe, Yuichiro ^d   Johkoh, Takeshi ^b,e   Ando, Masahiko ^a,f   Yamazaki, Naoya ^b,g   Seki, Akihiro ^h   Takemoto, Shinya ^h   Fukuoka, Masahiro ⁱ  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Independent Appropriate Use Advisory Board for Erlotinib   (Japan)

^c Japan Anti Tuberculosis Association   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^e Kinki Central Hospital of Mutual Association of Public School Teachers   (Japan)

^f NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g NATIONAL CANCER CENTER HOSPITAL   (Japan)

^h CHUGAI PHARMACEUTICAL CO LTD   (Japan)

ⁱ Izumi Municipal Hospital   (Japan)

Author keywords

Erlotinib; Interstitial lung disease (ILD); Nonsmall cell lung cancer; Safety; Surveillance

Indexed keywords

ERLOTINIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BENIGN TUMOR; BLEEDING; BLOOD DISEASE; BREAST DISEASE; CANCER MORTALITY; CONNECTIVE TISSUE DISEASE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; EAR DISEASE; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; GENITAL SYSTEM DISEASE; HEART DISEASE; HEPATOBILIARY DISEASE; HUMAN; INCIDENCE; INFECTION; INFESTATION; INJURY; INNER EAR DISEASE; INTERSTITIAL LUNG DISEASE; JAPANESE; KIDNEY DISEASE; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; OVERALL SURVIVAL; PARONYCHIA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; RECURRENT CANCER; RESPIRATORY TRACT DISEASE; RISK ASSESSMENT; SKIN DISEASE; THORAX DISEASE; URINARY TRACT DISEASE; VASCULAR DISEASE;

EID: 84863834864     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182598abb     Document Type: Article

References (21)

1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
2. Kubota K, Nishiwaki Y, Tamura T, et al. Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study. J Thorac Oncol 2008;3:1439-1445.
3. Takahashi T, Yamamoto N, Nukiwa T, et al. Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer. Anticancer Res 2010;30:557-563.
4. Yamamoto N, Horiike A, Fujisaka Y, et al. Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Cancer Chemother Pharmacol 2008;61:489-496.
5. Yoshida S. Results of gefitinib prospective investigation. Med Drug J 2005;41:772-789.
6. Kudoh S, Kato H, Nishiwaki Y, et al.; Japan Thoracic Radiology Group. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 2008;177:1348-1357.
7. Reck M, van Zandwijk N, Gridelli C, et al. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J Thorac Oncol 2010;5:1616-1622.
8. Tsuboi M, Le Chevalier T. Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors. Med Oncol 2006;23:161-170.
9. Azuma A, Kudoh S. High prevalence of drug-induced pneumonia in Japan. JMAJ 2007;50:405-411.
10. Saito Y Gemma A. [The cutting-edge of medicine; current state of drug-induced lung disease]. Nippon Naika Gakkai Zasshi 2011;100:199-207.
11. Saravanan V Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford) 2004;43:143-147.
12. Ohnishi K, Sakai F, Kudoh S, Ohno R. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia 2006;20:1162-1164.
13. Inokuma S, Sato T, Sagawa A, et al. Proposals for leflunomide use to avoid lung injury in patients with rheumatoid arthritis. Mod Rheumatol 2008;18:442-446.
14. Ando M, Okamoto I, Yamamoto N, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2006;24:2549-2556.
15. Japan Lung Cancer Society Committee on Preparation of Guideline for Use of Gefitinib. Guideline for Use of Gefitinib. Chiba, Japan: The Society, 2005.
16. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003;21:2237-2246.
17. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-2158.
18. Mok T, Wu YL, Au JS, et al. Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer. J Thorac Oncol 2010;5:1609-1615.
19. Li CT, Marek M, Guclu SZ, et al. Smoking and prognostic factors in an observational setting in patients with advanced non-small cell lung carcinoma. J Cancer 2011;2:52-61.
20. Jnne PA, Gurubhagavatula S, Yeap BY, et al. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, Iressa) on an expanded access study. Lung Cancer 2004;44:221-230.
21. Mohamed MK, Ramalingam S, Lin Y, Gooding W, Belani CP. Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. Ann Oncol 2005;16:780-785.